Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation

J Heart Lung Transplant. 2016 Feb;35(2):256-8. doi: 10.1016/j.healun.2015.10.009. Epub 2015 Oct 8.

Authors

Jonathan D W Evans¹, Stephen J Pettit¹, Martin Goddard², Clive Lewis¹, Jayan K Parameshwar¹

Affiliations

¹ Transplant Unit.
² Pathology Department, Papworth Hospital National Health Service Foundation Trust, Papworth Everard, Cambridge, United Kingdom.

PMID: 26508724
DOI: 10.1016/j.healun.2015.10.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Giant Cells / pathology
Heart Transplantation*
Humans
Male
Myocarditis / drug therapy*
Myocarditis / etiology
Myocarditis / pathology
Postoperative Complications
Recurrence

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Alemtuzumab